Envision Healthcare Corporation Company Profile (NYSE:EVHC)

Envision Healthcare Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "EVHC."

Envision Healthcare Corporation (NYSE:EVHC) released its earnings results on Tuesday, May, 2nd. The company reported $0.69 earnings per share for the quarter, hitting analysts' consensus estimates of $0.69. The firm earned $1.88 billion during the quarter, compared to the consensus estimate of $2.52 billion. Envision Healthcare Corporation had a positive return on equity of 5.75% and a negative net margin of 9.16%. View Envision Healthcare Corporation's Earnings History.

11 equities research analysts have issued 1 year price objectives for Envision Healthcare Corporation's stock. Their predictions range from $26.00 to $90.00. On average, they expect Envision Healthcare Corporation's share price to reach $72.13 in the next twelve months. View Analyst Ratings for Envision Healthcare Corporation.

Here are some recent quotes from research analysts about Envision Healthcare Corporation stock:

• 1. According to Zacks Investment Research, "Envision Healthcare Corporation is optimistic about the consolidating physician services market. It had an active start to the acquisition strategy for 2017, having completed four acquisitions in Physician Services in Jan 2017 and the buyout of Imaging Advantage LLC, in Apr 2017. The company is in the process of selling its once indispensable medical transportation business American Medical Response (AMR) to focus on physician staffing. The company, however, suffers from high indebtedness. It has about 4.3 times EBITDA, which is above the 3 to 4 times EBITDA that the company feels comfortable at. Also, its operating expense is on the rise and exceeding revenue growth. The company’s shares have underperformed the Zacks categorized Medical Outpatient and Home Healthcare industry, year to date." (7/7/2017)
• 2. Cantor Fitzgerald analysts commented, "Tweaking 2017-18 estimates. Historically, EVHC’s sequential jump in SG&A is about $57 million (including $17 million from legacy AMSG) in the first quarter, but since the merger closed late in 4Q16 we do not have a full quarter profile as a base. Our revised estimates assume slightly higher SG&A expenses and slightly lower depreciation and amortization. We are lowering our 1Q17 adjusted EBITDA estimate slightly to $291 million from $301 million, our 2017 adjusted EBITDA to $1.383 billion from $1.424 billion, and our 2018 adjusted EBITDA estimate to $1.537 billion from $1.581 billion. Enthusiastic about strategic options. We believe EVHC’s strategic review of its AMR and Envision Health segments could generate substantial proceeds and increase the company’s focus on its core physician services business. The AMR ambulance business accounted for $18 million (25%) of the shortfall in 4Q16 adjusted EBITDA, and the Evolution population health services business accounted for $10 million, or about 15%." (4/6/2017)
• 3. Jefferies Group LLC analysts commented, "Investors have been anticipating a volume-driven FY17 guidance miss for the last few months, as evidenced by the discount in its valuation, so last night's guidance shortfall, while wider than expectations, does not come as a surprise. We remain Buy-rated given our view that EVHC's fundamentals are intact; guidance is reasonable/conservative; valuation is compelling, and AMR sale could drive incremental share upside." (3/1/2017)
• 4. Canaccord Genuity analysts commented, "We maintain our BUY rating on the new EVHC and establish an $86 PT. The recently completed merger of AMSURG and Envision has created a company with unmatched scale in physician services, ambulatory surgery centers (ASCs), and medical transportation. With this combination, EVHC can offer a turn-key solution to health systems while garnering greater negotiating power with payers. The new company has sizable opportunities to cross-sell service lines into existing customers now that the merger is completed, an initiative that is expected to truly begin bearing fruit in 2018. Key highlights: Physician services will be the focus going forward. After recently meeting with mgmt., we walked away believing that physician services growth is the primary focus. The combined businesses of Sheridan and EmCare are now able to sell as one unit. We expect a key target area will be selling anesthesia services into the EmCare customer base as opportunities present. Additionally, mgmt. highlighted that acquisition opportunities remain plentiful. Early this week, EVHC purchased Alabama Neonatal Medicine, a small group that can leverage EVHC’s existing footprint throughout Alabama. What is intriguing about the merger is that the structure, now complete, provides the flexibility to continue to be active on the acquisition front. Ambulatory surgery center steady expansion. Based on our discussions with management, we expect EVHC to add roughly 10-15 ASC’s per year (currently operates 260)." (12/9/2016)

Some companies that are related to Envision Healthcare Corporation include IDEXX Laboratories (IDXX), Henry Schein (HSIC), Centene Corporation (CNC), DENTSPLY SIRONA (XRAY), Grifols, S.A. (GRFS), Genmab A/S (GNMSF), Olympus Corp. (OCPNY), DaVita HealthCare Partners (DVA), Align Technology (ALGN), Hologic (HOLX), Cooper Companies, Inc. (The) (COO), Universal Health Services (UHS), H. Lundbeck A/S- (HLUYY), IPSEN SA ADR (IPSEY), Perrigo Company (PRGO), ResMed (RMD), SONOVA HOLDING (SONVY) and Jazz Pharmaceuticals PLC (JAZZ).

Envision Healthcare Corporation's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vaughan Nelson Investment Management L.P. (1.25%), Hexavest Inc. (0.55%), Reinhart Partners Inc. (0.34%), Factory Mutual Insurance Co. (0.24%), BB&T Corp (0.09%) and Chevy Chase Trust Holdings Inc. (0.09%). Company insiders that own Envision Healthcare Corporation stock include John Thomas Gawaluck, Leonard M Riggs Jr, Randel G Owen, Robert Jon Coward, Todd G Zimmerman and William A Sanger. View Institutional Ownership Trends for Envision Healthcare Corporation.

Envision Healthcare Corporation's stock was sold by a variety of institutional investors in the last quarter, including Vaughan Nelson Investment Management L.P., Factory Mutual Insurance Co., AMI Asset Management Corp, Hexavest Inc., Independent Portfolio Consultants Inc., US Bancorp DE, Oregon Public Employees Retirement Fund and Exxonmobil Investment Management Inc. TX. View Insider Buying and Selling for Envision Healthcare Corporation.

Envision Healthcare Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Reinhart Partners Inc., BB&T Corp, Aperio Group LLC, Meeder Asset Management Inc., Douglas Lane & Associates LLC, Mn Services Vermogensbeheer B.V., APG Asset Management N.V. and Private Capital Management Inc.. View Insider Buying and Selling for Envision Healthcare Corporation.

Shares of Envision Healthcare Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Envision Healthcare Corporation stock can currently be purchased for approximately $62.61.